As CuraGen Mulls 454's Future, Three Options Emerge | GenomeWeb
NEW YORK (GenomeWeb News) – Ending months of speculation, CuraGen said publicly last week it has begun looking for strategic options for its majority stake in 454 Life Sciences.
The company cited as reasons the desire to “ensure funding for our advanced oncology pipeline and ensure that 454 Life Sciences has sufficient resources to support its growth and expansion.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.